Recombinant Mouse 4-1BB Ligand / TNFSF9 Protein, Fc Tag, 50 µg

Background
Tumor necrosis factor ligand superfamily member 9 (4-1BBL) is also known as 4-1BB ligand, CD137L or TNFSF9, which is a cytokine that binds to TNFRSF9. 4-1BBL is the high affinity ligand of 4-1BB. 4-1BBL induces the proliferation of activated peripheral blood T-cells. Also, 4-1BBL may have a role in activation-induced cell death (AICD). Furthermore, 4-1BBL may play a role in cognate interactions between T-cells and B-cells/macrophages. As for diseases, 4-1BBL is involved in cancers, infectious diseases and autoimmune diseases.

Source
Recombinant Mouse 4-1BB Ligand, Fc Tag (41L-M5257) is expressed from human 293 cells (HEK293). It contains AA Arg 104 - Glu 309 (Accession # NP_033430).
Predicted N-terminus: Arg 104

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 49.0 kDa. The protein migrates as 60-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity"
Hamouda, Filtjens, Brabants et al
Nat Commun (2024) 15 (1), 10635
(2) "Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects"
Ishibashi, Li, Hisatomi et al
Mol Ther Oncol (2024) 32 (4), 200893
(3) "In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer immunotherapy"
Pezzana, Blaess, Kortendieck et al
Theranostics (2024) 14 (12), 4582-4597
Showing 1-3 of 789 papers.